< Back

ABSTRACT

Corneal intraepithelial neoplasia as a cause of visual acuity decrease: a low-cost approach

doi: 10.24875/j.gamo.M18000131

Full Article in PDF (English)

Neoplasia intraepitelial corneal como causa de disminución de la agudeza visual: abordaje de bajo costo

doi: 10.24875/j.gamo.M17000088

Full Article in PDF (Spanish)


VOLUME 16 - NUMBER 5 / September-October (Clinical case / Caso clínico)


Alejandro Villarreal-González, Cirujano Oftalmólogo, Subespecialista en Córnea y Superficie Ocular, Jefe del Departamento de Córnea y Superficie Ocular, Centro Oftalmológico del Valle, San Pedro Garza García, N.L., México
Carlos Alberto Romo-Arpio, Cirujano Oftalmólogo, Subespecialista en Glaucoma y Segmento Anterior, Jefe del Departamento de Glaucoma, Centro Oftalmológico del Valle, San Pedro Garza García, N.L., México
Pablo Villarreal-Guerra, Cirujano Oftalmólogo, Maestría en Bioética y Educación Superior, Doctorando en Bioética, Profesor de Bioética y Oftalmología General, Universidad de Monterrey, San Pedro Garza García, N.L., México
Alejandro Sámano-Guerrero, Médico Cirujano y Partero, Investigador Clínico, Director de Consultora en Investigación Biomédica Analimed, San Pedro Garza García, N.L., México



Introduction: Intraepithelial corneal neoplasia is a dysplastic disease within the spectrum of ocular surface squamous neoplasia. It is a rare disease that is often subdiagnosed, especially when it presents in its diffuse form. When suspected, the diagnosis and treatment can be simple, even when we are dealing with a disease that can be disastrous. Case report: We present the case of a 63 year-old male patient that presents complaining of poor vision on the right eye with 2 weeks of evolution. Visual acuity maintained at 20/40 while corrected and at examination showed a superior corneal geographical lesion with frosted appearance. After other diseases were discarded, an epithelial scraping was performed and a low grade intraepithelial corneal neoplasia reported. Treatment with two series of 2 weeks of mitomycin C at 0.02% with three applications per day was decided accompanied with fluorometholone 0.1% at same dosage. Conclusions: The authors recommend the use of mytomicin C in countries in developing countries.


Keywords: Neoplasia. Cornea. Frosting. Epithelial. Mitomycin C. INFa-2B.